Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use.
To measure the user acceptance of a electronic auto-injector device (easypod) for recombinant human growth hormone (r-hGH) administration. This was an open-label, uncontrolled study in which participants (n = 61) were trained to use the device to administer subcutaneous recombinant human growth hormone (r-hGH). Participants' opinions on the device were recorded by questionnaire and/or telephone interview during training and after 15 and 60 days of use. Opinions on the device were also collected from nurses or physicians who trained the participants in device use. After 60 days, 98% (54/55) of responders reported a 'good' or 'very good' overall impression of the device. The pre-programmed dose feature, skin sensor, on-screen instructions, display of remaining dose, confirmation of injected dose and automatic needle attachment were identified by the majority of participants as 'very useful'. Participants were reported to have easily understood the injection process, and 87% (48/55) expressed a preference to continue use of the device. The device had a good safety profile, and no adverse events were reported during the study or follow-up periods. Participants had a good overall impression of the device and the majority expressed a preference to continue its use. The combination of features offered by the device make it user-friendly, and such ease of use may facilitate greater adherence to treatment, in turn improving therapy outcomes.